Across TCGA pan-cancer cohorts, MIR194-1 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of MIR194-1’s most consistent transcriptional readouts.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where MIR194-1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR194-1 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.
LIHC, LUSC, and BLCA are the cancer types where MIR194-1 tumor–normal differential expression is most reproducible.